226 related articles for article (PubMed ID: 1768039)
1. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
2. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
4. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer.
Lipponen P; Papinaho S; Eskelinen M; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(5):1533-8. PubMed ID: 1444217
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
6. Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Alhava E; Syrjänen K
Eur J Surg; 1991 May; 157(5):319-24. PubMed ID: 1678644
[TBL] [Abstract][Full Text] [Related]
7. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
8. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
10. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
Cherubini M; Baxa P; Guarino G
Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
[TBL] [Abstract][Full Text] [Related]
11. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.
Balleine RL; Earl MJ; Greenberg ML; Clarke CL
Br J Cancer; 1999 Mar; 79(9-10):1564-71. PubMed ID: 10188907
[TBL] [Abstract][Full Text] [Related]
12. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer.
Lipponen PK; Collan Y; Eskelinen MJ
Int Surg; 1991; 76(4):245-9. PubMed ID: 1663917
[TBL] [Abstract][Full Text] [Related]
13. Survival of women with node negative breast cancer in the Auckland region.
Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic value of laminin receptor expression in breast cancer survival.
Marques LA; Franco EL; Torloni H; Brentani MM; da Silva-Neto JB; Brentani RR
Cancer Res; 1990 Mar; 50(5):1479-83. PubMed ID: 2137368
[TBL] [Abstract][Full Text] [Related]
15. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
[TBL] [Abstract][Full Text] [Related]
20. Progesterone and estrogen receptors as prognostic variables in breast cancer.
Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]